FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 304:560-563 March 5, 1981 Number 10 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To study the effects of different types of progestogens on lipoprotein metabolism, we treated three groups of postmenopausal women (six subjects each) for three weeks with estradiol valerate, 2 mg per day, and continued the treatment with different sequential estradiol-progestogen regimens as follows: Group A received norethindrone acetate, 10 mg per day, from Day 15 to Day 24 of the cycle; Group B, medroxyprogesterone acetate, 10 mg per day; and Group C, norgestrel, 0.5 mg per day. These regimens were followed by two consecutive cycles. Total cholesterol decreased in all groups by 10 to 18 per cent from the base-line values (P < 0.05). High-density-lipoprotein (HDL) cholesterol decreased by 20 per cent from the base-line level during treatment with both the estradiol-norethindrone acetate (P < 0.05) and estradiol-norgestrel (P < 0.01) regimens, whereas estradiol with medroxyprogesterone acetate was not associated with a significant change in HDL cholesterol. Our results suggest that the androgenic progestogens of the 19-nortestosterone series reverse the beneficial effect of postmenopausal estrogen treatment on HDL cholesterol, whereas the hydroxyprogesterone derivative medroxyprogesterone acetate has no such effect.

This article has been cited by other articles:

• Alexandersen, P., Riis, B. J., Stakkestad, J. A., Delmas, P. D., Christiansen, C. (2001). Efficacy of Levormeloxifene in the Prevention of Postmenopausal Bone Loss and on the Lipid Profile Compared to Low Dose Hormone Replacement Therapy. J. Clin. Endocrinol. Metab. 86: 755-760 [Abstract] [Full Text]  
• Cheng, W., Lau, O. D., Abumrad, N. A. (1999). Two Antiatherogenic Effects of Progesterone on Human Macrophages; Inhibition of Cholesteryl Ester Synthesis and Block of Its Enhancement by Glucocorticoids. J. Clin. Endocrinol. Metab. 84: 265-271 [Abstract] [Full Text]  
• Weintraub, M. S., Grosskopf, I., Charach, G., Eckstein, N., Ringel, Y., Maharshak, N., Rotmensch, H. H., Rubinstein, A. (1998). Fluctuations of Lipid and Lipoprotein Levels in Hyperlipidemic Postmenopausal Women Receiving Hormone Replacement Therapy. Arch Intern Med 158: 1803-1806 [Abstract] [Full Text]  
• Prior, J. C. (1998). Perimenopause: The Complex Endocrinology of the Menopausal Transition. Endocr. Rev. 19: 397-428 [Abstract] [Full Text]  
• Alexandersen, P., Haarbo, J., Sandholdt, I., Shalmi, M., Lawaetz, H., Christiansen, C. (1998). Norethindrone Acetate Enhances the Antiatherogenic Effect of 17ß-Estradiol : A Secondary Prevention Study of Aortic Atherosclerosis in Ovariectomized Cholesterol-Fed Rabbits. Arterioscler. Thromb. Vasc. Bio. 18: 902-907 [Abstract] [Full Text]  
• Cagnacci, A., Mallus, E., Tuveri, F., Cirillo, R., Setteneri, A. M., Melis, G. B. (1997). Effect of Tibolone on Glucose and Lipid Metabolism in Postmenopausal Women. J. Clin. Endocrinol. Metab. 82: 251-253 [Abstract] [Full Text]  
• Zumoff, B., Crook, D., Stevenson, J. C., Daubresse, J.-C., Bluming, A. Z., Nabulsi, A. A., Folsom, A. R., White, A., Martin, K. A., Freeman, M. W. (1993). Hormone Replacement and Cardiovascular Risk Factors. NEJM 329: 1041-1043 [Full Text]